New cancer drug enters first human trials for advanced tumors
NCT ID NCT07473726
Summary
This is the first human study of a new cancer drug called HLX48, designed to test its safety and how it moves through the body. The trial will enroll 72 adults with advanced solid tumors that have stopped responding to standard treatments. Researchers will give increasing doses to find the highest safe amount patients can tolerate.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED/METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-Sen University Cancer Center
Guangzhou, Guangzhou, 716099, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.